Patrick Dolezal, an analyst from LifeSci Capital, maintained the Buy rating on Ibio. The associated price target remains the same with $5.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Patrick Dolezal has given his Buy rating due to a combination of factors tied to IBIO-610’s differentiated mechanism and favorable positioning. He views the recent WVE-007 results, despite investor disappointment, as validating the broader strategy of targeting activin E, supporting potential applications in combination with incretin therapies, in patients with obesity and type 2 diabetes, and in maintenance settings after initial weight-loss treatment.
He also emphasizes that iBio can leverage extensive emerging clinical data, including Wave’s and Arrowhead’s programs, to refine trial design, patient selection by BMI and visceral fat, and optimal treatment lines. With an IND for IBIO-610 anticipated in Q4 2026, a multi-year cash runway, and a clearly defined development path, he believes the risk-reward profile remains attractive at current valuation levels, supporting a Buy recommendation.
In another report released on March 18, Chardan Capital also maintained a Buy rating on the stock with a $5.00 price target.